This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
ZAVICEFTA (ceftazidime and avibactam), for the treatment of patients at high risk of MDR Gram-negative infections with suspected or documented P. aeruginosa, CRE (KPC, OXA-48), and ESBL- and AmpC-producing pathogens1-4.
ZAVICEFTA is indicated for the treatment of adult and paediatric patients aged 3 months and older with the following infections:1*
Complicated intra-abdominal infection (cIAI)
Complicated urinary tract infection (cUTI), including pyelonephritis
Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
Treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. ZAVICEFTA is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.†
*Consideration should be given to the official guidance on the appropriate use of antibacterial agents.1
†Data support the use of ZAVICEFTA in adult patients with limited treatment options including in primary bacteraemia, cSSTI, BJI, meningitis, febrile neutropenia, cystic fibrosis, post-transplant patients due to KPC and OXA-48 resistance mechanisms, and MDR Pseudomonas.7-21
Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.
ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.
Access our resources for implementation of an Antimicrobial Stewardship Programme and learn more about Pfizer initiatives to fight AMR
Abbreviations
BJI, bone and joint infection; cUTI, complicated urinary tract infection; cIAI, complicated intra-abdominal infection; cSSTI, complicated skin and soft-tissue infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase, BSI, bloodstream infection; cSSTI, complicated skin and soft tissue.
Prescribing information
Click here for Prescribing Information for Zavicefta® (ceftazidime and avibactam)
Click here for prescribing information for Meronem® (meropenem trihydrate)
Tygacil® (tigecycline)
Great Britain
Tygacil® (tigecycline) 50mg powder for solution for infusion
Northern Ireland
Tygacil® (tigecycline) 50mg powder for solution for infusion
References
Find out more about the efficacy of Zavicefta
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024